Difelikefalin (Korsuva): The Opioid Engineered So It Cannot Reach Your Brain (July 21, 2026)
Table of Contents
- A forty-year-old target with a compartment problem
- Four D-amino acids and a piperidine cap
- Why dialysis itch is not an antihistamine problem
- What KALM-1 and KALM-2 actually showed
- The pharmacokinetics are the quiet advantage
- The side effects that actually matter
- Where the peripheral restriction leaks
- The oral program, including the part that failed
- Where difelikefalin sits now
A forty-year-old target with a compartment problem
Kappa opioid receptor agonists have been known to suppress itch since the 1980s, and the pharmacology was never in doubt. The problem was location. Kappa receptors sit both on peripheral sensory nerve endings and throughout the central nervous system, and activating the central population produces dysphoria, sedation, depersonalization and hallucinations - not tolerable side effects for a symptom drug. Compound after compound reached the clinic on the strength of the peripheral effect and died on the central one. Difelikefalin does not solve this by tuning receptor affinity or by finding a subtype. It solves it by building a molecule that physically cannot get where the trouble is.
Four D-amino acids and a piperidine cap
Difelikefalin is a tetrapeptide: D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl, terminating in a 4-aminopiperidine-4-carboxylic acid group. Every residue is a D-amino acid, which matters twice. First, proteases are stereospecific - an all-D backbone is essentially invisible to the enzymes that would clear an ordinary tetrapeptide within minutes. Second, the combination of charge, hydrophilicity and bulk that this structure produces makes the molecule a poor candidate for passive diffusion across the blood-brain barrier. The peptide reaches kappa receptors on C-fiber terminals in the dermis, on keratinocytes, and on monocytes, T lymphocytes and mast cells. It largely does not reach the brain. And it has no meaningful activity at the mu opioid receptor anywhere, which is why there is no euphoria, no abuse potential, and - confirmed in a dedicated randomized trial at supratherapeutic 1.0 and 5.0 mcg/kg doses - no respiratory depression.
Why dialysis itch is not an antihistamine problem
Chronic kidney disease-associated pruritus affects a large share of hemodialysis patients and is badly undertreated, in part because the default therapy is wrong. Antihistamines fail in CKD-aP for the same reason they fail in most chronic itch: histamine is not the driver. The working model for uremic itch involves an imbalance in opioid tone - relatively increased mu signaling and relatively decreased kappa signaling in the skin and dorsal horn - layered on a peripheral inflammatory component from the uremic state itself. Difelikefalin engages both arms. Kappa activation on peripheral sensory terminals damps the afferent itch signal before it ascends. Kappa activation on immune cells and keratinocytes reduces release of pro-inflammatory mediators including prostaglandins. That a peripherally restricted kappa agonist works at all is itself a piece of clinical evidence for the non-histaminergic model.
What KALM-1 and KALM-2 actually showed
The pivotal program comprised two randomized, double-blind, placebo-controlled Phase 3 trials in adults on hemodialysis with moderate-to-severe pruritus: KALM-1 (NCT03422653), published in the New England Journal of Medicine in January 2020, and the global KALM-2 (NCT03636269). Dosing was 0.5 mcg/kg as an intravenous bolus into the venous line of the dialysis circuit at the end of each session, three times weekly, for 12 weeks. The primary endpoint was a reduction of at least 3 points on the 10-point Worst Itching Intensity Numerical Rating Scale. Across the program, roughly 40-51% of difelikefalin-treated patients hit that threshold at week 12, against roughly 20-28% on placebo, with parallel gains in itch-related quality of life. Read that honestly: the drug moves a substantial minority of patients across a clinically meaningful line, in a population where the alternatives are emollients, off-label gabapentin and hope. It is not an itch-abolishing drug, and the placebo response in itch trials is never small.
The pharmacokinetics are the quiet advantage
Dialysis patients are among the most heavily polypharmaceutical populations in medicine, which makes drug-interaction risk a first-order concern rather than a labeling detail. Difelikefalin is close to inert on that axis. It is not metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A. Plasma protein binding is 23-28%. Volume of distribution is around 238 mL/kg. It is excreted unchanged in urine and bile, with an elimination half-life near 2 hours and roughly 12 hours of effect after a single intravenous dose. Given three times a week into a circuit the patient is already attached to, the administration logistics add nothing to the treatment burden. For a class of molecules usually penalized on delivery, this is a case where the delivery constraint and the clinical setting happened to align.
The side effects that actually matter
The pooled Phase 3 safety analysis covered 848 subjects, including 278 aged 65 or older. The common adverse effects were diarrhea, vomiting and dizziness, plus somnolence, mental status changes and gait disturbances including falls. Two of those deserve emphasis. Diarrhea and vomiting are not minor events in a dialysis population, where dehydration and electrolyte or acid-base disturbance have short paths to serious consequences. And the sedation-adjacent effects - dizziness, somnolence, gait disturbance - are additive with centrally acting depressants, sedating antihistamines and opioid analgesics, all of which are common in this group. Somnolence ran about 7 percentage points higher in patients 65 and older. Peripheral restriction removes the catastrophic opioid risks; it does not remove the need for fall precautions.
Where the peripheral restriction leaks
It is worth noting that the barrier exclusion is functional rather than absolute. Rodent work published in Pharmacological Research in 2022 found that difelikefalin produces diuresis through a central kappa pathway - meaning enough drug reaches central receptors to drive at least one measurable central effect, even though the dysphoria and hallucinations that ended earlier kappa agonists do not appear at clinical doses. That is the correct way to hold the claim: peripheral restriction is a quantitative property that buys a therapeutic window, not a binary property that guarantees the brain is untouched.
The oral program, including the part that failed
An oral formulation was developed alongside the injection and tested well beyond dialysis. The most interesting result was KOMFORT, a Phase 2 trial published in the New England Journal of Medicine in February 2023, in which 126 patients with moderate-to-severe pruritus from notalgia paresthetica - a localized neuropathic itch of the upper back with no approved therapy - received 2 mg twice daily or placebo for 8 weeks. That program advanced toward Phase 2/3. The atopic dermatitis program did not. In December 2023, dose-finding Part A of KIND-1 showed that oral difelikefalin added to topical corticosteroids gave no meaningful benefit over topical corticosteroids alone, and the indication was dropped. That negative result is informative rather than damning: peripheral kappa agonism appears to help most where the itch is neuropathic or uremic and largely unaddressed, and to add little on top of effective topical anti-inflammatory therapy in an inflammatory dermatosis.
Where difelikefalin sits now
Intravenous difelikefalin was approved by the FDA in August 2021 as Korsuva and by the European Commission in April 2022 as Kapruvia, with further approvals including the UK, Switzerland, Canada and Australia; NICE recommended it for NHS use in England in 2023 on the back of a published cost-effectiveness analysis. Commercial rights to the approved product sit with Vifor Fresenius Medical Care Renal Pharma and CSL Vifor. Cara Therapeutics, which originated the molecule, narrowed to the notalgia paresthetica program in 2024 and merged into Tvardi Therapeutics in 2025 - so the current status of the oral program is a question to verify against primary sources rather than assume. What is not in question is the design lesson. Difelikefalin took a target that had defeated the field for forty years and made it drugable by changing where the molecule can go rather than what it binds. That is a strategy with more targets left in it than this one.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus (KALM-1) - New England Journal of Medicine, January 2020 Source
- [2] Phase 2 Trial of Difelikefalin in Notalgia Paresthetica (KOMFORT) - New England Journal of Medicine, February 2023 Source
- [3] Difelikefalin - StatPearls, NCBI Bookshelf (structure, mechanism, dosing, pharmacokinetics, adverse effects) Source
- [4] Safety and Tolerability of Difelikefalin for Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program - Kidney Medicine, 2022 Source
- [5] Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial - Clinical and Translational Science, 2021 Source
- [6] CR845-CLIN3103 (KALM-2): A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus - ClinicalTrials.gov NCT03636269 Source
- [7] Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus in People with Kidney Failure Receiving Haemodialysis - PharmacoEconomics, 2023 Source
- [8] Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND-1 Study Evaluating Oral Difelikefalin in Atopic Dermatitis (December 2023) Source
Related Articles
Skin and Anti-Aging Peptides: The Science Behind GHK-Cu
An evidence-based look at GHK-Cu, one of the most researched peptides in dermatology and anti-aging science.
Immune-Modulating Peptides: Thymosin Alpha-1 and Beyond
An overview of peptides studied for immune system modulation, from approved medications to emerging research.
Setmelanotide (Imcivree): The MC4R Peptide That Treats Obesity the GLP-1 Drugs Can't (June 26, 2026)
Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.